Work

Transition from Intravenous to Subcutaneous Daratumumab Formulation in Clinical Practice

Year: 2021

Type: article

Study design: Observational Study

Source: Clinical Lymphoma Myeloma & Leukemia

DOI: 10.1016/j.clml.2021.02.014

Authors: Issam S. Hamadeh, Donald C. Moore, Allison Martin, Allison Karabinos, Hailey Hill, Ami Ndiaye, Jordan D. Robinson, Barry A. Paul, Shebli Atrash, Manisha Bhutani, Peter M. Voorhees, Saad Z. Usmani

Institution: Levine Cancer Institute

Language: English

Topic: Multiple Myeloma Research and Treatments

Subfield: Hematology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funders: Amgen, Bristol-Myers Squibb, Genzyme, GlaxoSmithKline, Novartis, Sanofi, Leukemia and Lymphoma Society, Celgene, AbbVie, Array BioPharma, Takeda Pharmaceuticals U.S.A., MedImmune, Janssen Pharmaceuticals

OpenAlex ID: W3135519711

FWCI: 1.804

Cites: 19

Cited by: 16

Related to: 10